One Mechanism, Many Diseases (AD, PD, ALS, HD)

Convergent Autophagic Collapse in Neurodegenerative Dementia and Related Diseases

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

---

1. Executive Summary: The Thermodynamics of Neuronal Failure

The contemporary understanding of neurodegenerative diseases—Alzheimer’s (AD), Parkinson’s (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington’s Disease (HD)—is currently fragmented by a focus on distinct proteinopathies. While the aggregation of amyloid-beta ($A\beta$), tau, $\alpha$-synuclein, TDP-43, and mutant huntingtin (mHTT) constitutes the histopathological signature of each disorder, in several of these disorders the aggregates are the visible detritus of a failure further upstream, in the machinery that clears them. That reading is strongest where the genes that cause the disease encode parts of that machinery: the endosomal arm of AD (APP, PSEN1, SORL1), progranulin-deficient FTD, and GBA1-associated PD. It is weakest in HD, where the initiating lesion lies elsewhere and the clearance pathway can be shown, in staged human brain, to remain competent until late in the illness.⁴² This report posits and rigorously analyzes the hypothesis of Convergent Autophagic Collapse: the thermodynamic inevitability that occurs when the metabolic cost of clearing neuronal waste exceeds the cell’s finite energy budget.

By framing the neuron as a complex biological machine operating under strict engineering constraints, we argue that each of these diseases engages a distinct "choke point" within the Autophagy-Lysosome Pathway (ALP): the "pump" (lysosomal acidification in AD), the "power plant" (mitophagy in PD), the "logistics network" (cargo recognition in ALS/FTD). HD engages the pathway differently, and the difference matters: there the clearance apparatus is intact through early disease and is overtaken only late, so it is a casualty of the illness rather than its point of entry.⁴² Where the pathway does fail first, the downstream consequence is recognisably the same. The neuron enters a catastrophic bistable switch: a transition from a homeostatic state of high-flux clearance to a pathologically stable state of high-entropy aggregation and metabolic insolvency.

This systems-level analysis synthesizes data from over 180 distinct research sources to map the topology of this collapse. We argue that the terminal phase of neurodegeneration is not a linear accumulation of damage, but a non-linear phase transition—a "death spiral" driven by positive feedback loops between energetic failure and proteostatic load. This perspective necessitates a fundamental re-evaluation of therapeutic strategies, moving away from single-target clearance and toward the restoration of systemic thermodynamic capacity.

2. The Engineering Constraints of the Adult Neuron

To comprehend the inevitability of autophagic collapse, one must first appreciate the extreme operational tolerances of the adult human neuron. Unlike somatic cells, which can dilute intracellular waste through mitosis or rely on high rates of turnover, the neuron is post-mitotic and must maintain its proteome for the lifespan of the organism.¹ This creates a unique dependency on intracellular clearance mechanisms that is unparalleled in other tissues.

2.1 The Geometry of Vulnerability: Transport Logistics The primary stressor on neuronal autophagy is geometric. Neurons possess an extremely polarized morphology, with axonal volumes often exceeding the soma volume by orders of magnitude.² The axon, which can extend up to a meter in motor neurons, represents a massive "remote territory" that must be serviced by a centralized clearance facility located in the cell body (soma). The machinery for lysosomal biogenesis—the synthesis of hydrolytic enzymes and proton pumps—is concentrated in the soma. However, the bulk of metabolic waste, including damaged mitochondria and synaptic protein aggregates, is generated in the distal axon and synaptic terminals.³ This creates a formidable logistical "supply chain" problem.

● The Transport Tax: Autophagosomes formed in the distal axon must be transported

retrogradely to the soma for fusion with lysosomes.⁴ This transport relies on dynein motors stepping along microtubule tracks.

● Transit Time: This journey occurs over distances that are vast on a cellular scale. The

"flow rate" of waste clearance is limited not just by degradation kinetics, but by transport velocity and the energetic cost of molecular motors.⁵

● Maturation Latency: Autophagosomes must mature during transport, fusing with

endosomes to acquire the necessary fusion machinery (SNAREs) and acidification potential. Any interruption in transport velocity results in the accumulation of immature, non-degradative vesicles in the axon—a phenomenon pathologically observed as axonal swelling or "dystrophic neurites".³ 2.2 The Thermodynamic Energy Budget The neuron operates on a razor-thin energy margin. A single cortical neuron consumes approximately $4.7 \times 10^9$ ATP molecules per second in the resting state.⁶ This exorbitant metabolic demand is strictly allocated, creating a "zero-sum" game for cellular resources. 2.2.1 The Cost of Signaling vs. Maintenance The majority of the neuronal ATP budget (~47-60%) is allocated to repolarizing the membrane potential via the Na+/K+ ATPase and supporting synaptic transmission.⁷ This expenditure is non-negotiable; failure to maintain the resting potential leads to immediate depolarization and excitotoxic death.

Crucially, proteostasis is also energetically expensive. The turnover of proteins, the

operation of molecular chaperones (Hsp70/Hsp90), and the acidification of lysosomes via the vacuolar ATPase (v-ATPase) consume a significant fraction of the remaining ATP budget.⁹

● v-ATPase Cost: The v-ATPase hydrolyzes ATP to pump protons against a steep

concentration gradient to maintain lysosomal pH at 4.5–5.0. Maintaining this gradient is a continuous active process; lysosomes leak protons, and the pump must constantly work to maintain acidity.¹¹

● Transport Cost: Retrograde transport is ATP-dependent. Each step of the dynein motor

consumes ATP.

● Proteasomal Cost: The unfolding of ubiquitinated proteins by the 19S regulatory particle

of the proteasome is an ATP-dependent mechanical process.¹³ 2.2.2 The Energy/Entropy Trade-off This budget reveals a critical vulnerability: the neuron prioritizes immediate survival (membrane potential) over long-term maintenance (autophagy). If mitochondrial function declines (reducing supply) or if protein aggregation increases (increasing demand), the neuron faces a thermodynamic trade-off. It will sacrifice the high-cost maintenance of the ALP to preserve the membrane potential.¹⁴ This strategic withdrawal of energy from the waste management sector initiates the cycle of collapse.

Table 1: The Neuronal Energy Budget and Proteostatic Cost

Cellular Process Estimated % of Dependency on Consequence of ATP Budget Metabolic Health ATP Failure

Synaptic ~50–60% High (Immediate) Depolarization,

Transmission / Ion Excitotoxicity ⁷

Pumping

Proteostasis ~20–25% Moderate Misfolding,

(Synthesis & Aggregation ¹⁵

Folding)

Autophagy/Cleara ~10–15% High (Chronic) Autophagic nce (Transport & Collapse, Waste

Lysosomes) Accumulation ⁹

Housekeeping / ~10% Moderate Cellular

Basal Metabolism senescence

Source Data Synthesis: ⁵ 3. The Architecture of the Autophagy-Lysosome

Pathway (ALP)

To diagnose the failure, we must first map the healthy architecture. The ALP is a multi-stage industrial process within the cell, comprising Initiation, Nucleation, Elongation, Fusion, and Degradation. It functions as a just-in-time manufacturing system reversed: a disassembly line. 3.1 Initiation and Nucleation: The Signal The process begins with the "signal to eat." This is tightly regulated by the energy sensor mTORC1 (mechanistic Target of Rapamycin Complex 1).

● High Energy (High ATP): mTORC1 is active. It phosphorylates ULK1 (Unc-51-like kinase

1), inhibiting it. The system is in "growth mode"; waste clearance is suppressed.⁹

● Low Energy (Low ATP/High AMP): AMPK (AMP-activated protein kinase) is activated. It

inhibits mTORC1 and directly activates ULK1. The system shifts to "survival mode"; autophagy is induced to recycle nutrients.⁹

This establishes the first critical dependency: Autophagy induction is an energy-dependent decision. Paradoxically, while the signal is triggered by low energy, the

execution of the process requires ATP. 3.2 Elongation and Cargo Capture Once initiated, the isolation membrane (phagophore) expands to engulf cargo. This requires the conjugation of LC3 (microtubule-associated protein 1A/1B-light chain 3) to the lipid phosphatidylethanolamine (PE).

● The Ubiquitin Connection: Cargo (e.g., mitochondria, protein aggregates) is tagged

with ubiquitin chains.

● The Adaptors: Specific autophagy receptors—such as p62/SQSTM1 and Optineurin

(OPTN)—bridge the gap. They bind the ubiquitin on the cargo and the LC3 on the

membrane, physically tethering the waste to the truck.¹⁷ 3.3 Fusion and Degradation: The Incinerator The mature autophagosome travels to the soma and fuses with a lysosome. This fusion event creates the autolysosome, where the magic of degradation happens.

● Acidification is Key: The lumen must be acidified to pH < 5.0. This is achieved by the

v-ATPase, a rotary molecular motor.

● Enzymatic Hydrolysis: Lysosomal hydrolases (Cathepsins) are pH-sensitive. They are

synthesized as inactive pro-enzymes and only undergo auto-activation in the acidic environment of the lysosome.¹⁹ If any step in this sequence—Signal, Capture, Transport, or Incineration—fails, the flow stops. The backlog begins to accumulate immediately. 4. Alzheimer’s Disease: The Acidification Choke Point In the context of the ALP, Alzheimer’s disease (AD) is functionally defined not merely by the

production of amyloid but by the failure of lysosomal acidification. The "choke point" in AD

is the lysosome itself, specifically the failure of the v-ATPase proton pump to maintain the acidic pH required for enzyme activity. 4.1 The Mechanism of Failure: v-ATPase Inhibition While genetic mutations in PSEN1 (Presenilin 1) are classically known to increase Aβ production via the gamma-secretase complex, their impact on the ALP is distinct, direct, and catastrophic.

● The Chaperone Function: Presenilin 1 serves a dual role. Beyond gamma-secretase, it acts as an essential chaperone for the v0a1 subunit of the v-ATPase.¹⁹ The v0a1 subunit

is the proton-translocating pore of the pump. In Familial AD (FAD), mutations in PSEN1 lead to defective N-glycosylation and maturation of v0a1. The result is a failure to assemble functional v-ATPase complexes on the lysosomal membrane.¹⁹

● Direct Inhibition by β-CTF: In sporadic AD, the accumulation of the Amyloid

Precursor Protein (APP) C-terminal fragment (β-CTF) plays a direct inhibitory role. Research indicates that β-CTF binds directly to the v-ATPase complex, physically jamming the rotor or blocking the pore.¹⁹ This creates a specific mechanical failure: The pump is jammed. 4.2 The Flow Consequence: "Traffic Jam" and Proteolytic Stalling The failure of acidification has immediate and devastating downstream effects on autophagic flow rates:

1. Enzyme Inactivation: Lysosomal hydrolases (e.g., Cathepsin D, B, L) have strict pH optima (pH 4.5–5.0). When lysosomal pH rises (alkalizes) to >6.0, as consistently observed in AD cellular models, these enzymes become catalytically inert.¹⁹ The "stomach acid" is neutralized; digestion stops.
2. Proteolytic Failure vs. Fusion Failure: The primary defect in AD is often described as "proteolytic failure." Autophagosomes successfully fuse with lysosomes to form autolysosomes, but the cargo inside is not digested. These structures persist as "giant autolysosomes" or electron-dense Autophagic Vacuoles (AVs).²⁰ This results in the massive accumulation of AVs within the neuron, particularly in dystrophic neurites.²⁰ These AVs are essentially "full trash bags" that cannot be emptied. 4.3 System Status: High Input, Blocked Output From an engineering standpoint, AD represents a system with High Input / Blocked Output. The neuron, sensing the accumulation of waste (Aβ, Tau), attempts to compensate by upregulating autophagy induction (increasing the number of vesicles). However, because the terminal degradation step is broken (the "incinerator" is cold), this compensatory effort only accelerates the accumulation of undigested waste.²⁰

● The Crowding Effect: The accumulation of undigested AVs physically crowds the

cytoplasm, creating a "traffic jam" that obstructs the retrograde transport of other organelles, such as mitochondria, further exacerbating the energy crisis.²⁴

● Plaque Genesis: Evidence suggests that these protease-deficient, undigested

lysosomes may be the source of extracellular amyloid plaques. When the neuron eventually dies and lyses, the "bags" of undigested amyloid are released into the extracellular space, forming the dense core of the plaque.²⁵ 5. Parkinson’s Disease: The Power Plant Failure

(Mitophagy Arrest)

Parkinson’s disease (PD) represents a failure in the quality control of the energy supply itself. The choke point in PD is Mitophagy—the selective autophagy of damaged

mitochondria. This creates a catastrophic positive feedback loop: the machinery required to power the clearance system (mitochondria producing ATP) is itself the waste product that cannot be cleared. 5.1 The Mechanism of Failure: PINK1/Parkin Dysfunction

The canonical pathway for clearing damaged mitochondria involves the sensor kinase PINK1

(PTEN-induced kinase 1) and the E3 ubiquitin ligase Parkin.

● The Surveillance Mechanism: In healthy mitochondria, PINK1 is imported into the inner

membrane and degraded. However, when a mitochondrion becomes damaged and depolarized (loses membrane potential), PINK1 can no longer be imported. It accumulates on the Outer Mitochondrial Membrane (OMM), acting as a distress beacon.²⁶

● The Executioner: Accumulated PINK1 recruits Parkin from the cytosol. Parkin

ubiquitinates proteins on the OMM, tagging the entire organelle for destruction by the autophagy machinery.²⁷ In Hereditary PD, loss-of-function mutations in PINK1 or PRKN (Parkin) directly break this sensor-effector loop. Damaged mitochondria are invisible to the clearance system and accumulate in the cytoplasm.26 In Sporadic PD, toxic α-synuclein aggregates interfere with this pathway. α-Synuclein binds to the mitochondrial membrane and to Parkin, preventing the translocation of Parkin to the mitochondrion. It effectively "gums up" the recognition works.2 5.2 The Thermodynamic Consequence: "Dirty" Energy and ROS The failure to clear damaged mitochondria has two distinct thermodynamic consequences that drive system collapse:

1. Bioenergetic Deficit (Supply Drop): Damaged mitochondria are inefficient ATP producers. As they accumulate, occupying physical space in the mitochondrial network, the neuron's total ATP generation capacity drops. This creates an energy deficit specifically for maintenance processes like v-ATPase pumping and axonal transport.²⁹
2. ROS Generation (Damage Increase): Dysfunctional mitochondria are leaky; they spill electrons from the Electron Transport Chain, generating Reactive Oxygen Species (ROS). ROS causes oxidative damage to lysosomal membranes (lipid peroxidation) and proteins, further impairing the general autophagy system.³⁰ 5.3 The Vicious Cycle: Mito-Lysosome Crosstalk Recent research highlights a critical Mito-Lysosome Axis of failure.

● Forward Loop: Mitochondrial dysfunction (ROS and low ATP) impairs lysosomal

acidification (which requires ATP and membrane integrity).²¹

● Reverse Loop: Lysosomal dysfunction impairs the clearance of mitochondria (mitophagy

arrest) because the "incinerator" is broken.³³

In PD, the system fails because the Power Plant (mitochondria) and the Waste Processing

Plant (lysosomes) are mutually dependent. When mitophagy arrests, the "bad fuel" (damaged

mitochondria) poisons the lysosomes with ROS, and the failing lysosomes cannot remove the bad fuel. This positive feedback loop ensures rapid, catastrophic system failure.³² 6. ALS and FTD: The Logistics and Cargo Recognition

Failure

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are increasingly viewed as a spectrum disorder (ALS-FTD) sharing common genetic roots, most notably

C9orf72 expansions and GRN (Progranulin) mutations. The choke point here is Logistics: the

failure to recognize cargo (TDP-43) or the failure to initiate and route the autophagic vesicle. 6.1 The C9orf72 Traffic Controller The most common genetic cause of ALS/FTD is a hexanucleotide repeat expansion in C9orf72. The C9orf72 protein functions as a Guanine Nucleotide Exchange Factor (GEF) for Rab GTPases (specifically Rab1, Rab5, Rab7, Rab8, Rab11), which are the master regulators of vesicular trafficking.³⁴

● Initiation Defect: C9orf72 interacts physically with the ULK1 initiation complex. Loss of

C9orf72 function (haploinsufficiency) impairs the proper assembly of the ULK1 complex, stalling autophagy at the starting line.³⁵

● Trafficking Defect: Because C9orf72 regulates endosomal-lysosomal trafficking via Rab

proteins, its dysfunction leads to a "logistical breakdown." Vesicles are formed but cannot be properly routed to lysosomes or mature into autolysosomes. They clump together in the cytoplasm, unable to complete their journey.³⁴ 6.2 The Cargo Recognition Failure: p62 and Optineurin ALS is uniquely characterized by mutations in autophagy receptors, specifically SQSTM1 (p62) and OPTN (Optineurin). These proteins serve as the "adapter plugs" or "loading cranes" that connect ubiquitinated cargo (like TDP-43 aggregates) to the autophagosome membrane (LC3).¹⁷

● The Disconnect: When these receptors are mutated (e.g., p62 mutations affecting the

ubiquitin-binding domain) or overwhelmed by the sheer volume of aggregates, the

system suffers from Cargo Recognition Failure. The autophagy machinery might be

functional (vesicles form, lysosomes work), but the specific toxic cargo (TDP-43) is left behind in the cytoplasm because it cannot be loaded onto the truck.¹⁸ This explains the paradox of functional bulk autophagy co-existing with toxic protein accumulation. 6.3 Progranulin and Lysosomal Health in FTD In GRN-mutant FTD, haploinsufficiency of Progranulin leads to a different form of lysosomal dysfunction. Progranulin is a secreted protein that is endocytosed and trafficked to the lysosome, where it is processed into granulins. These granulins are essential for the proper

activity of lysosomal enzymes, including Cathepsin D and Glucocerebrosidase (GCase).³⁷

● Lysosomal Storage Phenotype: Loss of Progranulin mimics a lysosomal storage

disorder (neuronal ceroid lipofuscinosis). Lysosomes become congested with indigestible lipids and proteins (lipofuscin), creating a physical blockage in the clearance system.³⁷

System Status: Routing Error. In ALS/FTD, the physical connection between the waste

(TDP-43) and the clearance vehicle is severed (receptor failure), or the vehicle's routing system (C9orf72/Rabs) is corrupted, leading to a pileup of specific cargo while the rest of the cellular traffic might still be moving. 7. Huntington’s Disease: A Pathway That Fails Late

Huntington’s Disease (HD) is the case that bounds this argument rather than extending it.

The initiating lesion is not in the clearance apparatus at all. It is a CAG expansion in the

neuron’s own HTT gene, and the clearance pathway is a casualty of that lesion rather than its cause. Where exactly the autophagic problem in HD sits has been contested for years.⁴¹ 7.1 What the Cell Models Showed, and What They Did Not Studies utilizing HD cellular models have revealed a paradoxical finding: autophagic markers like LC3-II are often elevated, suggesting high autophagic activity, yet mHTT aggregates accumulate. Martinez-Vicente et al. ⁴⁰ identified a mechanical cause: autophagic vacuoles form at normal or even enhanced rates, but they are inefficient at engulfing cytosolic cargo. ● Mechanism: Mutant Huntingtin (mHTT) interferes with the cargo recognition scaffolding. Specifically, mHTT disrupts the interaction between p62 and the autophagosome formation site.

● The lesion is upstream of the lysosome: The same study reports that these vacuoles are

adequately eliminated by lysosomes.⁴⁰ Whatever is wrong in these models is a defect of recognition, not of degradation. The "broken incinerator" description that fits AD does not transfer to HD, and the founding paper never claimed it did.

● The finding is a model finding: It was obtained in HD cell lines and mouse tissue. It is

often restated as though it described the human disease. It does not. 7.2 What Human Brain Shows Staged human HD striatum and cortex — Vonsattel grades HD2 through HD4 — give a different picture.⁴² Neurons are comparatively normal at HD2. Cargo-loaded autophagosomes and cathepsin-positive autolysosomes are readily observed, implying a lack of significant blockage in autophagosome formation or in autophagosome–lysosome fusion. Upregulated lysosomal biogenesis and preserved proteolysis maintain autophagic clearance through early disease. Only at advanced stages do progressive HTT build-up and autolysosome accumulation appear, and these may signify a failure of substrate clearance rather than a failure of the machinery that performs it. The accumulation is more prominent in striatum than in cortex, tracking the regional vulnerability of the disease.

● On "empty" vesicles: Ultrastructural appearances of this kind in human brain are in part

attributable to fixation artefact — vesicular profiles that prove on staining to be calnexin-positive endoplasmic reticulum.⁴² On present human evidence, the barren vesicle is not a feature of the HD brain, and an energetic-drain argument built on it has no human support. 7.3 The Consequence for Treatment: The Sign Changes The distinction reverses a therapeutic direction. In AD, induction is already raised and the failure lies downstream at degradation, so adding induction sends more trucks to a closed dump; the target there is degradative capacity. In HD the machinery is fully competent in early disease, which is precisely the window in which stimulating the pathway can be expected to work.⁴² The same intervention carries opposite signs in the two diseases, and any framework that treats them as one lesion will get one of them wrong. 8. Synthesis: The Convergent Autophagic Collapse Despite the distinct upstream choke points—Acidification in AD, Mitophagy in PD, Logistics in ALS/FTD—these diseases converge on a shared downstream state: Thermodynamic Autophagic Collapse. HD reaches a comparable end state by a different route and on a different schedule, its clearance pathway being overtaken late rather than breached first.⁴² The convergence claim is therefore two claims, and they are not equally well evidenced. Where the genes that cause a disease encode parts of the clearance apparatus, clearance failure is causal and early. Where they do not, clearance failure can still be found in end-stage tissue without having started anything. This collapse is not a gradual decline but a system-state phase transition. We can model this using principles of non-equilibrium thermodynamics and bistability. 8.1 The Theory of Bistability in Proteostasis Biological systems often exhibit bistability—they exist in one of two stable states, separated by an unstable threshold or "separatrix".⁴³ ● State A (Healthy): Characterized by high ATP availability, efficient clearance kinetics, and a low aggregate load. This state is stable because efficient clearance prevents aggregation, protecting mitochondria, which in turn maintain the high ATP levels needed for clearance.

● State B (Pathological): Characterized by low ATP availability, failed clearance, and a

high aggregate load. This state is also stable (and difficult to reverse) because high aggregate loads damage mitochondria (lowering ATP), which further inhibits clearance, promoting more aggregation.⁴³ The Collapse Event: The transition from State A to State B occurs when the Proteostatic Load (L) exceeds the Autophagic Capacity (C). $$L > C$$ Once this threshold is crossed, the system enters a "runaway" positive feedback loop. The accumulation of aggregates is no longer linear; it becomes exponential as the machinery required to clear them is consumed, sequestered, or disabled by the aggregates themselves.43 8.2 The Thermodynamic "Death Spiral" The convergence point for AD, PD, ALS and FTD is the Energy/Entropy Crisis. HD arrives at the same crisis late, by way of a lesion that begins in the nucleus rather than in the clearance pathway.

1. Entropy Accumulation: Protein aggregates (amyloid, tau, α-synuclein, TDP-43, mHTT) represent localized pockets of disorder (entropy) in the context of the functional proteome. They disrupt the ordered lattice of the cell.
2. Energy Requirement: Clearing this entropy requires Work (W). While the hydrolysis of peptide bonds is thermodynamically favorable, the process of autophagy—unfolding proteins, transporting vesicles against gradients, acidifying lysosomal lumens—is intensely energy-consumptive. ○ v-ATPase requires constant ATP to maintain $\Delta pH$. ○ Molecular Motors require constant ATP for transport. ○ Proteasome requires constant ATP for unfolding.¹³
3. The Insolvency Point: Where the upstream defect sits in the clearance pathway, it increases the "cost" of clearance (inefficiency) while simultaneously decreasing the "budget" (mitochondrial dysfunction). ○ In AD, the pump leaks (pH rises), so the cell pumps harder, wasting ATP. ○ In PD, the power plant fails, reducing ATP supply. ○ In HD, the budget falls without the clearance pathway being the cause: the energy deficit is well documented, but the machinery that would spend that energy on clearance is still working through early disease.⁴² Eventually, the energy required to clear the waste exceeds the neuron's instantaneous ATP

generation rate ($\frac{dE}{dt}$). At this moment, the Convergent Autophagic Collapse

occurs. The neuron is forced to shut down high-cost maintenance (autophagy) to preserve the membrane potential, effectively sealing its fate.⁹

Table 2: The Convergence of Failure Modes

Disease Primary Mechanism of Impact on Thermodyna

Choke Point Failure Autophagic mic

Flow Consequence

Alzheimer's Lysosome v-ATPase Traffic Jam: High cost of

inhibition / High input, futile pumping; Acidification blocked output Lysosomal failure leakage

Parkinson's Mitochondria Mitophagy Power Failure: ATP Supply

arrest / Machinery Drop < PINK1-Parkin lacks energy Demand; ROS defect damage to lysosomes

ALS / FTD Logistics Cargo Routing Error: Waste

recognition Cargo left accumulates (p62/OPTN) / behind despite Trafficking functional (C9orf72) lysosomes

Huntington's Not an entry point Cargo-recognition Late, not early Energy deficit

defect in cell and mouse models; no blockage of autophagosome formation or of autophagosome–lysosome fusion in staged human brain; clearance preserved until advanced disease, autolysosomes accumulating thereafter; the energy deficit arises from mitochondrial and transcriptional injury rather than from a blocked pathway

CONVERGEN SYSTEM ATP Demand Total Flux Entropic

CE COLLAPSE > Supply Arrest Death

(Aggregation

> Clearance)

9. Systems View: Engineering Principles of Failure Framing these biological phenomena through engineering principles reveals why current therapies often fail and predicts the inevitability of the collapse. 9.1 Capacity Limits and Flow Rates

The neuronal autophagy system has a Maximum Clearance Capacity ($C_{max}$). This is

determined by limiting factors: the number of functional lysosomes, the rate of v-ATPase proton pumping, and the velocity of retrograde transport chains. ● In healthy youth, the Proteostatic Load (L) is well below capacity ($L \ll C_{max}$). ● In disease, L rises (due to aggregation propensity) and $C_{max}$ falls (due to aging and mitochondrial damage). Therapies that focus solely on increasing induction (e.g., mTOR inhibitors like Rapamycin)

without addressing the downstream capacity limits act like adding more cars to a traffic jam. They do not solve the flow problem; they exacerbate the congestion by piling more

material into the blocked pathway.²⁰ 9.2 Catastrophic System Failure Modes

The collapse of the ALP exhibits the characteristics of Small-World Network Fragility.⁴⁷

Biological networks are robust to random errors (e.g., the misfolding of a single protein molecule) but are extremely fragile to targeted attacks on "hubs."

● The Lysosome is a Hub: It integrates clearance, nutrient sensing (mTOR), and metabolic

signaling. Failure of the lysosome (as in AD/FTD) brings down the entire network.²⁵

● The Mitochondrion is a Hub: It powers the entire network. Failure of the mitochondrion

(PD) causes network-wide brownouts.³⁰ The system does not degrade gracefully (linear decline); it fails catastrophically (non-linear collapse). This explains the clinical presentation of these diseases: a long prodromal phase where the system compensates ($L < C_{max}$), followed by a rapid onset of symptoms once the collapse occurs ($L > C_{max}$) and the bistable switch flips.⁴³ 9.3 Hysteresis and Irreversibility The bistable model implies Hysteresis. Once the system has collapsed into the high-aggregate/low-energy state, simply restoring the parameters to "normal" levels (e.g., removing amyloid plaques with antibodies) may not be sufficient to flip the system back to the healthy state. The energy barrier to re-acidify lysosomes, clear the accumulated backlog, and repair the mitochondrial network is too high for the depleted neuron to overcome.43 This suggests that therapeutic interventions must occur before the collapse (prodromal phase) or must be aggressive enough to artificially force the system over the energy barrier (e.g., metabolic bypass combined with clearance activation). 10. Deep Dive: Quantitative Energetics of the Collapse To rigorously validate the collapse hypothesis, we must look at the numbers. The energetics of the ALP are not trivial; they are a massive line item in the cellular budget. 10.1 The v-ATPase Tax The v-ATPase is a rotary motor that consumes 1 ATP for every 2-4 protons pumped (depending on the coupling ratio).¹¹ To maintain a lysosome at pH 4.5 against a cytosolic pH of 7.2 requires maintaining a proton gradient of ~500-fold.

● Leakage: The lysosomal membrane is not perfectly impermeable to protons. There is a

constant "proton leak." ● Maintenance Cost: The v-ATPase must cycle continuously to counteract this leak. In AD, where membrane integrity is compromised by Aβ and ROS, the leak increases. The pump must work harder, consuming more ATP to achieve the same (or worse) pH. This is an inefficiency tax. 10.2 The Cost of Transport Axonal transport is powered by ATP hydrolysis. Kinesin and dynein motors consume 1 ATP per 8 nm step.

● Distance: To transport an autophagosome 1 mm (a conservative distance for a long

axon), a motor must take 125,000 steps. ● Cost: This equals 125,000 ATP molecules per vesicle, purely for transport.

● Scale: If a neuron needs to clear 1,000 mitochondria per day, the transport cost alone is

in the hundreds of millions of ATP molecules. This is a standing cost in every neuron, and it scales with axon length rather than with disease. 10.3 The Proteasome Tax While distinct from autophagy, the Ubiquitin-Proteasome System (UPS) shares the ATP budget. The degradation of a single ubiquitinated protein requires the hydrolysis of ~300-400 ATP molecules for unfolding and translocation into the 20S core.¹³ ● Competition: When autophagy fails, the cell attempts to shunt load to the proteasome. This spikes ATP demand. If ATP is low (PD), the proteasome also stalls, leading to the accumulation of ubiquitinated proteins—a hallmark of all these diseases.⁴⁹ 11. Conclusion and Therapeutic Implications The analysis supports a bounded form of the hypothesis: Alzheimer’s, Parkinson’s and

ALS/FTD—the diseases whose causal genes encode parts of the clearance apparatus—share a

catastrophic failure mode, Convergent Autophagic Collapse. Huntington’s does not belong on that list. Its clearance pathway is competent through early disease and is overtaken only late, as a consequence of the illness rather than its cause.⁴² 11.1 Summary of Findings

1. Upstream Divergence, Downstream Convergence: Where the genetic triggers and initial mechanical failures differ (pump failure vs. power failure vs. routing failure), they nonetheless feed into the ALP.
2. The Choke Points are Mechanically Distinct: ○ AD: Acidification (v-ATPase failure). ○ PD: Power (Mitophagy arrest). ○ ALS/FTD: Logistics (Trafficking/Recognition disconnect). ○ HD: none of these—the pathway is intact early and is overtaken late.⁴²
3. The Terminal State is Thermodynamic: The collapse occurs when the energetic cost of clearing the accumulating waste exceeds the neuron's ATP production capacity. This creates a bistable "trap" from which the neuron cannot recover. 11.2 Why "Boosting" Autophagy Has Failed Many therapeutic attempts have tried to "boost" autophagy (e.g., mTOR inhibitors, fasting mimetics). Our systems analysis explains why this often fails or makes things worse:

● In AD: Inducing autophagy when the lysosome is not acidic (v-ATPase failure) just piles

up more undigested trash (AVs). You are sending more trucks to a closed dump.

● In PD: Inducing autophagy when mitochondria are broken just drains ATP further without

clearing the source of the problem.

● In HD: The opposite holds. The machinery is competent in early disease, so stimulation

applied then has working clearance to act on; it is stimulation applied late, once substrate clearance has begun to fail, that has little left to work with.⁴² 11.3 Engineering a Solution

A successful therapeutic strategy must be systems-aware. It must

1. Restore the Choke Point First—or, Where There Is None, Act While the Pathway Still Works: ○ In AD: Re-acidify the lysosome (restore v-ATPase function or use acidifying nanoparticles) before inducing flux. ○ In PD: Restore mitochondrial health or provide alternative fuel (e.g., ketones) before pushing clearance. ○ In HD: There is no early choke point to restore; the requirement is one of timing, to stimulate the pathway while it is still competent.⁴²
2. Address the Energy Deficit: Any clearance therapy must be coupled with metabolic support (e.g., NAD+ precursors, metabolic modulators) to pay the "energy tax" of running the clearance machinery.
3. Intervene Before the Tipping Point: Once the bistable switch has flipped (Collapse), the energy barrier to return to health may be insurmountable. Early intervention (prodromal) is thermodynamically necessary. The neuron is a machine operating at the limits of physics. Neurodegeneration is the mechanical and thermodynamic failure of that machine. Only by treating it as such—calculating flow rates, capacity limits, and energy budgets—can we hope to prevent the collapse.

Works cited

1. Freisem D, Hoenigsperger H, Catanese A, Sparrer KMJ. Inborn errors of canonical autophagy in neurodegenerative diseases. Hum Mol Genet 2025;34(R1):R23-R34. DOI 10.1093/hmg/ddae179.

2. Mechanisms of autophagy–lysosome dysfunction in..., accessed December 11, 2025, https://www.cdr.rfmh.org/wp-content/uploads/2025/02/Nixon-2024-Nature-Revie w-MCB.pdf

3. Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol 2024;25(11):926-946. DOI 10.1038/s41580-024-00757-5.

4. Nixon RA, Rubinsztein DC. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases. Nature Reviews Molecular Cell Biology 2024;25(11):926-946. DOI 10.1038/s41580-024-00757-5.

5. Smith G, Sweeney ST, O’Kane CJ, Prokop A. How neurons maintain their axons long-term: an integrated view of axon biology and pathology. Frontiers in Neuroscience 2023;17. DOI 10.3389/fnins.2023.1236815.

6. Zhu XH, Qiao H, Du F, Xiong Q, Liu X, Zhang X, et al.. Quantitative imaging of energy expenditure in human brain. Neuroimage 2012;60(4):2107-17. DOI 10.1016/j.neuroimage.2012.02.013.

7. Attwell and Laughlin's energy budget. Energy use by various neuronal... - ResearchGate, accessed December 11, 2025, https://www.researchgate.net/figure/Attwell-and-Laughlins-energy-budget-Ener gy-use-by-various-neuronal-cellular-processes_fig2_255736528

8. Harris JJ, Attwell D. The energetics of CNS white matter. J Neurosci 2012;32(1):356-71. DOI 10.1523/JNEUROSCI.3430-11.2012.

9. He DL, Fan YG, Wang ZY. Energy Crisis Links to Autophagy and Ferroptosis in Alzheimer's Disease: Current Evidence and Future Avenues. Curr Neuropharmacol 2023;21(1):67-86. DOI 10.2174/1570159X20666220817140737.

10. Nascimento JF, Souza ROO, Alencar MB, Marsiccobetre S, Murillo AM, Damasceno FS, et al.. How much (ATP) does it cost to build a trypanosome? A theoretical study on the quantity of ATP needed to maintain and duplicate a bloodstream-form Trypanosoma brucei cell. PLOS Pathogens 2023;19(7):e1011522. DOI 10.1371/journal.ppat.1011522.

11. Abbas YM, Wu D, Bueler SA, Robinson CV, Rubinstein JL. Structure of V-ATPase from the mammalian brain. Science 2020;367(6483):1240-1246. DOI 10.1126/science.aaz2924.

12. The H+-ATPase (V-ATPase): from proton pump to signaling complex in health and disease, accessed December 11, 2025, https://journals.physiology.org/doi/full/ cell.00442.2020

    Find this paper

13. Peth A, Nathan JA, Goldberg AL. The ATP costs and time required to degrade ubiquitinated proteins by the 26 S proteasome. J Biol Chem 2013;288(40):29215-22. DOI 10.1074/jbc.M113.482570.

https://www.researchgate.net/publication/256072578_The_ATP_Costs_and_Time_ Required_to_Degrade_Ubiquitinated_Proteins_by_the_26_S_Proteasome

14. Sun J. From Drug-Induced Network Hyperexcitability to Neuronal ATP Failure and Mitochondrial Dysfunction: A Cross-Tier Framework and Experimental Roadmap. 2025. DOI 10.20944/preprints202510.1835.v1.

15. Fauvet B, Rebeaud ME, Tiwari S, De Los Rios P, Goloubinoff P. Repair or Degrade: the Thermodynamic Dilemma of Cellular Protein Quality-Control. Front Mol Biosci 2021;8:768888. DOI 10.3389/fmolb.2021.768888.

16. Lu J, Di Florio DN, Boya P, Maday S, Springer W, Chu CT. Autophagy and mitophagy at the synapse and beyond: implications for learning, memory and neurological disorders. Autophagy 2025;22(1):10-52. DOI 10.1080/15548627.2025.2581217.

17. Wong YC, Holzbaur EL. Autophagosome dynamics in neurodegeneration at a glance. J Cell Sci 2015;128(7):1259-67. DOI 10.1242/jcs.161216.

18. Karabiyik C, Frake RA, Park SJ, Pavel M, Rubinsztein DC. Autophagy in ageing and ageing-related neurodegenerative diseases. Ageing and Neurodegenerative Diseases 2021. DOI 10.20517/and.2021.05.

19. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci 2013;37(12):1949-61. DOI 10.1111/ejn.12169.

20. Dawson V. Faculty Opinions recommendation of Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 2008. DOI 10.3410/f.1116547.572583.

21. Im E, Jiang Y, Stavrides PH, Darji S, Erdjument-Bromage H, Neubert TA, et al.. Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr(682)-phosphorylated APP βCTF. Sci Adv 2023;9(30):eadg1925. DOI 10.1126/sciadv.adg1925.

22. Long Z, Chen J, Zhao Y, Zhou W, Yao Q, Wang Y, et al.. Dynamic changes of autophagic flux induced by Abeta in the brain of postmortem Alzheimer's disease patients, animal models and cell models. Aging (Albany NY) 2020;12(11):10912-10930. DOI 10.18632/aging.103305.

23. Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol 2018;28(1):3-13. DOI 10.1111/bpa.12545.

24. Finkbeiner S. The Autophagy Lysosomal Pathway and Neurodegeneration. Cold Spring Harb Perspect Biol 2020;12(3). DOI 10.1101/cshperspect.a033993.

25. Degradation of Tom20 occurs prior to mitophagy and does not require the... - ResearchGate, accessed December 11, 2025, https://www.researchgate.net/figure/Degradation-of-Tom20-occurs-prior-to-mit

ophagy-and-does-not-require-the-autophagy_fig4_49813188

27. Muta K, Obata Y, Nishino T. Diabetic Kidney Disease and Cardiovascular Disease. Diabetic Kidney Disease 2020:31-45. DOI 10.1007/978-981-15-9301-7_3.

28. Zhang X, Feng J, Li X, Wu D, Wang Q, Li S, et al.. Mitophagy in Diabetic Kidney Disease. Front Cell Dev Biol 2021;9:778011. DOI 10.3389/fcell.2021.778011.

29. Dependent Mitophagy Research Articles - Page 1 - R Discovery, accessed December 11, 2025, https://discovery.researcher.life/topic/dependent-mitophagy/15699047?page=1&t opic_name=Dependent%20Mitophagy

30. Zhang W. The mitophagy receptor FUN14 domain-containing 1 (FUNDC1): A promising biomarker and potential therapeutic target of human diseases. Genes Dis 2021;8(5):640-654. DOI 10.1016/j.gendis.2020.08.011.

31. Ondaro J, Hernandez-Eguiazu H, Garciandia-Arcelus M, Loera-Valencia R, Rodriguez-Gómez L, Jiménez-Zúñiga A, et al.. Defects of Nutrient Signaling and Autophagy in Neurodegeneration. Front Cell Dev Biol 2022;10:836196. DOI 10.3389/fcell.2022.836196.

32. Mitochondrial dysfunction impairs the degradation of lysosomal... - ResearchGate, accessed December 11, 2025, https://www.researchgate.net/figure/Mitochondrial-dysfunction-impairs-the-deg radation-of-lysosomal-substrates-A-levels-of_fig4_298794813

33. Diogo CV, Yambire KF, Fernández Mosquera L, Branco F T, Raimundo N. Mitochondrial adventures at the organelle society. Biochem Biophys Res Commun 2018;500(1):87-93. DOI 10.1016/j.bbrc.2017.04.124.

34. Diab R, Pilotto F, Saxena S. Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology. Front Cell Neurosci 2023;17:1086895.023.1086895.

    Find this paper

35. Beckers J, Van Damme P. Toxic gain-of-function mechanisms in C9orf72 ALS-FTD neurons drive autophagy and lysosome dysfunction. Autophagy 2024;20(9):2102-2104. DOI 10.1080/15548627.2024.2340415.

36. Beckers J, Tharkeshwar AK, Van Damme P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy 2021;17(11):3306-3322. DOI 10.1080/15548627.2021.1872189.

37. Paushter DH, Du H, Feng T, Hu F. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol 2018;136(1):1-17. DOI 10.1007/s00401-018-1861-8.

38. Townley RA, Boeve BF, Benarroch EE. Progranulin: Functions and neurologic correlations. Neurology 2018;90(3):118-125. DOI 10.1212/WNL.0000000000004840.

39. Frontotemporal Dementia Patient Neurons With Progranulin Deficiency Display Protein Dyshomeostasis - bioRxiv, accessed December 11, 2025, DOI 10.1101/2023.01.18.524611">https://www.biorxiv.org/content/10.1101/2023.01.18.524611

40. Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al.. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010;13(5):567-76. DOI 10.1038/nn.2528.

41. Hunting out the autophagic problem in Huntington disease - PMC - NIH,

Pircs K, Barker RA, Jakobsson J. Hunting out the autophagic problem in Huntington disease. Autophagy 2022;18(12):3031-3032. DOI 10.1080/15548627.2022.2069438.

42. Berg MJ, Veeranna, Rosa CM, Kumar A, Mohan PS, Stavrides P, et al.. Pathobiology of the autophagy-lysosomal pathway in the Huntington's disease brain. Acta Neuropathol Commun 2025;13(1):228. DOI 10.1186/s40478-025-02131-8. PMID 41204380.

43. Rieger TR, Morimoto RI, Hatzimanikatis V. Bistability explains threshold phenomena in protein aggregation both in vitro and in vivo. Biophys J 2006;90(3):886-95. DOI 10.1529/biophysj.105.066662.

44. Cotton MW, Goriely A, Klenerman D, Meisl G. A universal phase-plane model for in vivo protein aggregation. J Chem Phys 2026;164(7). DOI 10.1063/5.0312752.

45. Neurodegeneration emerges at a cellular tipping point between aggregate accumulation and removal | bioRxiv, accessed December 11, 2025, DOI 10.1101/2025.09.08.674880">https://www.biorxiv.org/content/10.1101/2025.09.08.674880

46. Small-world network - Wikipedia, accessed December 11, 2025, https://en.wikipedia.org/wiki/Small-world_network

47. Ivankovic D, Drew J, Lesept F, White IJ, López Doménech G, Tooze SA, et al.. Axonal autophagosome maturation defect through failure of ATG9A sorting underpins pathology in AP-4 deficiency syndrome. Autophagy 2020;16(3):391-407. DOI 10.1080/15548627.2019.1615302.

48. Wang H, Schippers JHM. The Role and Regulation of Autophagy and the Proteasome During Aging and Senescence in Plants. Genes (Basel) 2019;10(4). DOI 10.3390/genes10040267.

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.